On February 4, Chongqing Pharmaceutical Holdings (000950) issued an announcement on the progress of the proposed change in the equity structure of the controlling shareholder. The company disclosed a relevant indicative announcement on January 11, 2025. Chongqing Chemical and Pharmaceutical Holdings (Group) Co., Ltd., a shareholder of the controlling shareholder Chongqing Pharmaceutical and Health Industry Co., Ltd., and Chongqing Yufu Holdings Group Co., Ltd. signed an equity transfer contract, intending to transfer 49% of Chongqing Chemical and Pharmaceutical Holdings to Chongqing Yufu. It is worth noting that the actual controllers of Chongqing Chemical and Pharmaceutical Group and Chongqing Yufu are both the Chongqing State-owned Assets Supervision and Administration Commission.

According to the announcement, as of January 27, 2025, the company has received the "Notice Letter" from Chongqing Medical Health, confirming that Chongqing Chemical and Pharmaceutical Group has obtained the approval of the Chongqing State-owned Assets Supervision and Administration Commission, and the equity transfer contract has come into effect. Next, the equity transfer still needs to go through the relevant procedures such as industrial and commercial change registration.

In the first three quarters of 2024, Chongqing Pharmaceutical Holdings achieved revenue of 59.693 billion yuan and net profit attributable to shareholders of the parent company of 292 million yuan.

Source: https://finance.eastmoney.com/